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How can we get better?Prostate cancer (PCa) is the second most common cancer in
men with 17 million new cases in 2018 and 27 million new
cases expected by 2040 [1]. Mortality is however declining
which may reflect improvements in the treatments avail-
able [2]. One such treatment is the robot-assisted laparo-
scopic prostatectomy (RALP) which was first performed in
2000 at the Department of Urology of Frankfurt University
in Germany. Initial adoption was limited due to the lack of
data supporting its safety and efficacy in terms of func-
tional and oncological outcomes until the landmark studies
published by Menon et al. [3,4]. This paved the way for
further studies such as the Swedish LAPRO trial. This
revealed a moderate advantage for erectile dysfunction
with RALP, compared to open radical retropubic prosta-
tectomy (RRP), and no significant difference between the
two in terms of cancer relapse at the 24-month follow-up
[5]. Consequently, the Da Vinci Robot is currently used
worldwide, with an estimated 300 000 urology procedures
being performed in 2018 [6].
Higher-volume centres have traditionally been associ-
ated with more favourable outcomes across a wide range of
surgical procedures and conditions [7]. These have signifi-
cant implications on both training and adoption of new
techniques. As such, it is imperative to calculate the
number of cases a surgeon needs to perform to ensure
competency and safety at any new technique.
This learning curve is influenced by patient factors such
as case mix and surgeon related factors like attitude,
confidence and experience in other procedures. It also
differs depending on the desired outcome. For example,
the number of cases required to reduce positive surgical
margins (PSMs) may be 300 while reducing the mean esti-
mated blood loss (EBL) may only require 200.
In an attempt to quantify the RALP-related learning
curve, multiple studies have been performed, each
focusing on different surgical outcomes and usingPeer review under responsibility of Second Military Medical
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notable of these studies was a retrospective analysis
of 3 794 patients undergoing RALP, performed by three
different surgeons, between January 2003 and September
2009 conducted by Sooriakumaran et al. [8]. This revealed
that greater surgical experience resulted in an improved
PSM rate and operative time (OT), but this required over
1 600 cases for a PSM of <10% and 750 cases for OT to
plateau. This suggested a longer than expected learning
curve, limiting its use to high volume surgeons to optimise
patient outcomes.
In this study, a laparoscopic naı̈ve surgeon’s experience
with 500 patients in mainland China was monitored and the
RALP learning curve characterised in terms of OT, EBL, PSM,
biochemical recurrence (BCR), postoperative continence
and length of stay (LOS). A transperitoneal approach with
six trocar access points and a conventional four-arm Da
Vinci Robotic System was used.
The study identified that the OT and EBL declined
initially, reaching a plateau at 200 cases, followed by a
second dramatic decline after 400 cases. A similar pattern
was also observed with the postoperative LOS, with a
plateau reached after 200 cases. In terms of postoperative
continence, only 3.8% of patients were incontinent at the
36-month follow-up, while the BCR rate was 14.2% 13-
months postoperatively. Unlike Sooriakumaran et al. [8]
however, the PSM remained at 21.8% overall, with no sig-
nificant reduction being observed with increased exper-
eince. These results are in-keeping with the outcomes of
other high-volume centres which suggest that despite the
efficacy of RALP, further treatment with either radiotherapy
(RT) or chemotherapy is required to improve survival.
Studies such as radical radiotherapy (Radicals-RT) and
SPCG-15 are therefore very important. Radicals-RT is a
randomised controlled trial (RCT) which suggests that early
salvage RT should be the standard treatment of care after
radical prostatectomies (RPs), instead of adjuvant RT, a
finding supported by the ARTISTIC meta-analysis [9]. This
recommendation is based on both treatment modalitieson and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
178offering similar outcomes for event-free survival, but salvage
RT spares many men from RT and its associated side-effects.
SPCG-15 goes one step further, aiming to investigate
whether RPRT improves cause-specific survival compared
to primary RT and androgen deprivation treatment in pa-
tients with locally advanced PCa [10]. This RCT is currently
underway, with patient recruitment ending in 2022, and is
likely to impact the future management of PCa, making it
an important trial to follow.
In conclusion, RALP is a safe, minimally invasive proced-
urewith good oncological outcomes and desirable functional
results. Nevertheless, to achieve expertise in this technique,
with a reduction of PSM to <10%, a longer than expected
learning curve is required, limiting its use to high-volume
centres. Additionally, further work is required to identify the
ideal treatment modality to improve survival post-RP.
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